Searched for
PD 1 INHIBITOR
Chinese medicines bring relief to India’s cancer patientsIndia’s cancer treatment landscape is seeing a shift as lower-cost immunotherapy drugs developed in China and marketed through Indian partn...- GSK re-enters India’s cancer drug marketGlaxoSmithKline Pharmaceuticals is re-entering India's oncology market with the launch of Jemperli and Zejula, precision therapies for gyna...
- GSK enters into oncology segment; launches therapies for gynaecological cancersGlaxoSmithKline Pharmaceuticals has entered the oncology segment in India, introducing Jemperli and Zejula for gynaecological cancers. Thes...
- Zydus Life's plans for cancer biosimilar hit a legal hurdleThe Delhi High Court has granted an interim injunction against Zydus Lifesciences, an Ahmedabad-based drug maker, following a patent infrin...
- Cancer cure found? Scientists create a new mRNA vaccine that triggers strong anticancer immune response against tumoursUniversity of Florida scientists have engineered an experimental mRNA vaccine that stimulates the immune system to combat tumors in conjunc...
- These large- and mid-cap stocks can give more than 30% return in 1 year, according to analystsIf market volatility is worrying you, just consider three things. An earnings season is set to start; valuations are not cheap; and last, b...
- Bristol Myers agrees up to $11.1 billion deal with BioNTech to shake up cancer immunotherapyThe deal, which includes $3.5 billion in unconditional payments, underpins BioNTech's ambition to continue a costly long-term focus on expe...
- These mid-cap stocks with ‘strong buy’ & ‘buy’ recos can rally over 26%, according to analystsThere are earnings seasons and their earnings seasons. While every earnings season is important, some are more important than others as the...
- Stocks to buy today: IndusInd Bank gets a downgrade; Motilal Oswal sees over 20% upside in Sun PharmaNuvama has downgraded IndusInd Bank to "Reduce" citing concerns over internal derivative trades and management changes, while Antique remai...
- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsInvestors with high exposure to mid-caps should start planning for Q3 earnings and how the stocks in their portfolio will react to them. So...
- Dr Reddy's Laboratories shares rise 2% after launching drug to treat nasopharyngeal cancerDr Reddy's Laboratories has launched toripalimab, an immune oncology drug for adults with recurrent or metastatic nasopharyngeal carcinoma ...
- Dr Reddy's launches drug for neck, head cancerDr Reddy's Laboratories launched toripalimab, an immune oncology drug for adults with a rare form of head and neck cancer, in India. This d...
- Dr Reddy's launches novel cancer therapy Toripalimab in IndiaDr. Reddy’s has launched Toripalimab, a novel immuno-oncology drug, in India for treating recurrent or metastatic nasopharyngeal carcinoma ...
- Dr Reddy's launches immuno-oncology drug Toripalimab in India for treating nasopharyngeal carcinomaDr. Reddy's Laboratories launched Zytorvi (Toripalimab), a novel immunotherapy drug for recurrent or metastatic nasopharyngeal carcinoma (N...
- Don’t pop that pill daily: Doctors red-flag proton pump inhibitors used to treat acid reflux, heartburnsThe reason for the popularity of PPIs among doctors and patients is not tough to gauge. With unhealthy lifestyles and dietary habits, acidi...
- Glenmark gets USFDA nod to begin trials for potential cancer drugThe USFDA approval paves the way for Glenmark's subsidiary Glenmark Specialty to proceed with a Phase 1/2, first-in-human, clinical study o...
- World Cancer Day: Immunotherapy can help patients suffering from carcinoma of the lungsImmunotherapy should be given as early as possible to achieve a lasting remission of the disease.
- Medical breakthrough! Aurigene closer to developing cancer treatment capsuleThe Bengaluru-based company is an independent subsidiary of Dr Reddy’s Laboratories and its United States-based partner Curis Inc.
- Aspirin can boost immunotherapy in cancer patientsGiving cancer patients aspirin at the same time as immunotherapy could dramatically boost the effectiveness of the treatment, according to ...
- DRL's Aurigene ties up with US firm CurisCuris has agreed to make payments of up to $52.5 million per programme including $42.5 million for approval and commercial milestones,
Load More
